NuShores Biosciences

NuShores Biosciences is developing the NuCress™ scaffold, a novel bone regeneration technology targeting large segmental bone defects (>2.5 cm) resulting from trauma, cancer, or warfare. The company holds an exclusive global license to patented intellectual property developed from over $15 million in grant-funded research at the University of Arkansas at Little Rock. While not yet FDA-cleared or commercially available, NuCress™ has demonstrated promising safety and efficacy in extensive preclinical animal studies across multiple species. NuShores operates as a pre-revenue, private entity aiming to address a significant unmet need in orthopedic, dental, and cranio-maxillofacial reconstruction.

NuCress™ scaffold: A hydrophilic, polymeric bone scaffold with controllable design, shape, and form. It incorporates DBM and HA, swells in situ to lock into defects, and is designed for shelf-stability and ease of surgical use.

NuShores competes in the synthetic bone graft segment against products from large medtech companies (e.g., Medtronic's INFUSE, Stryker's Vitoss) and other biomaterial firms. Its key claimed differentiators are its handling properties, in-situ swelling fixation, and targeted efficacy in large defects. It also indirectly competes with allograft processors and autograft procedures, aiming to displace them by offering a superior synthetic alternative.